FBW7 is a tumor suppressor that is mutated in a wide spectrum of human cancers, and FBW7 functions as a haplo-insufficient tumor suppressor in mice.
| Institute |
|---|
| Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151461 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Biochemistry;Cancer |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | F-box/WD repeat-containing protein 7 (FBW7, Cdc4) |
| Reactivity: | Human ; Mouse |
| Clone: | FBOX 3a9/1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | F-Box And WD Repeat Domain Containing 7; F-Box Protein FBX3; SEL-1; Fbx3; HCdc4; FBW7; Hago; Homolog Of C Elegans Sel-1; F-Box Protein SEL-1; Archipelago Homolog; F-Box Protein FBW7; Archipelago; FBXO3; FBXW6; CDC4; FBW6; AGO |
|---|---|
| Product description: | SCF (Skp, Cullin, F-box containing complex) ubiquitin ligases regulate the degradation of many proteins involved in the control of cell division and growth. F-box proteins are the SCF components that bind to substrates, and this binding is usually signaled by substrate phosphorylation. The FBW7/Cdc4 F-box protein was first recognized by its ability to bind cyclin E, and the SCF (FBW7) is now known to target c-Myc, c-Jun and Notch for degradation in addition to its role in cyclin E proteolysis. FBW7 thus negatively regulates several key oncoproteins. Accordingly, FBW7 is a tumor suppressor that is mutated in a wide spectrum of human cancers, and FBW7 functions as a haplo-insufficient tumor suppressor in mice. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Synthetic peptide of human sequence |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | SCF (Skp, Cullin, F-box containing complex) ubiquitin ligases regulate the degradation of many proteins involved in the control of cell division and growth. F-box proteins are the SCF components that bind to substrates, and this binding is usually signaled by substrate phosphorylation. The FBW7/Cdc4 F-box protein was first recognized by its ability to bind cyclin E, and the SCF (FBW7) is now known to target c-Myc, c-Jun and Notch for degradation in addition to its role in cyclin E proteolysis. FBW7 thus negatively regulates several key oncoproteins. Accordingly, FBW7 is a tumor suppressor that is mutated in a wide spectrum of human cancers, and FBW7 functions as a haplo-insufficient tumor suppressor in mice. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Tu et al. 2013. PLoS One. 8(7):e68574. PMID: 23840897. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. Nateri et al. 2004. Science. 303(5662):1374-8. PMID: 14739463. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.